Ewa Jassem

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 522 citations · Full text

Inbuild Trial, Parallel-group Trial, Advanced Lung Disease +5

BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer

Rafael Rosell, Marcin Skrzypski, Ewa Jassem et al. · PLoS ONE · 2007 · 209 citations · Full text

Integration of Gene Dosage and Gene Expression in Non-Small Cell Lung Cancer, Identification of HSP90 as Potential Target

Mariëlle I. Gallegos Ruiz, Karijn Floor, Paul Roepman et al. · PLoS ONE · 2008 · 119 citations · Full text

Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study

Olivier Lortholary, Marie‐Olivia Chandesris, C. Bulaï Livideanu et al. · The Lancet · 2017 · 119 citations · Full text

Medicine, Mast Cell Disorder, Allergy +1

Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung

Marcin Skrzypski, Ewa Jassem, Miquel Tarón et al. · Clinical Cancer Research · 2008 · 115 citations